HLS Therapeutics Inc
HLS
Company Profile
Business description
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
Contact
10 Carlson Court
Suite 701
Etobicoke
TorontoONM9W 6L2
CANT: +1 647 495-9000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
86
Stocks News & Analysis
stocks
5 star fully franked ASX dividend payer
Investors in cheap ASX share with a narrow moat enjoys a high yield, but there are risks investors should be aware of.
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,886.60 | 35.90 | 0.41% |
| CAC 40 | 8,082.60 | 4.12 | 0.05% |
| DAX 40 | 25,435.20 | 60.78 | 0.24% |
| Dow JONES (US) | 51,481.51 | 347.11 | -0.67% |
| FTSE 100 | 10,704.77 | 19.89 | 0.19% |
| HKSE | 24,523.57 | 118.94 | -0.48% |
| NASDAQ | 26,820.38 | 248.34 | -0.92% |
| Nikkei 225 | 65,481.27 | 396.35 | -0.60% |
| NZX 50 Index | 13,683.63 | 147.05 | -1.06% |
| S&P 500 | 7,683.69 | 59.72 | -0.77% |
| S&P/ASX 200 | 8,709.30 | 29.60 | 0.34% |
| SSE Composite Index | 3,830.45 | 6.83 | 0.18% |